There’s only one Company that have at test in a box CODX
fabriz03
Posts
-
-
Let her rip tater chip
-
They do not make the test kits
-
Medical equipment including coronavirus testing kits distributed by the W.H.O. arrived in Dubai for delivery to Iran on Monday
-
Let her rip tater chip
-
Just remember everyone is going to need a test ️
-
Co-Diagnostics, Inc Chief Scientific Officer to Address Bipartisan Commission on Biodefense in Washington, D.C.
by Co-Diagnostics | Mar 12, 2020 | News Release |
Salt Lake City, Utah – March 5, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that Dr. Brent Satterfield PhD, Chief Scientific Officer and co-founder of Co-Diagnostics, will address a meeting held by the Bipartisan Commission on Biodefense in Washington, D.C. on March 18, 2020. The focus of the meeting will be to address national biodefense in light of the response to COVID-19, and its implications for preparedness.
Co-Diagnostics was the first U.S. company to receive a CE-mark for a COVID-19 diagnostic test. The Company is currently shipping orders for its test to countries on 5 continents, including shipments to Italy, the most severely impacted country in the European Union. The Company continues to scale up production to meet global demand, and is also seeking emergency use clearance for use as an in vitro diagnostic by the U.S. FDA as well as by the CDSCO in India, both of which are expected to further increase the domestic and international reach of this powerful and cost-effective diagnostic tool
The rapid development of the Company’s COVID-19 test was made possible by a unique, proprietary design process and patented CoPrimer technology platform that was invented by Dr. Satterfield. Prior to founding Co-Diagnostics in 2013, Dr. Satterfield developed new diagnostic platforms for groups such as the Department of Homeland Security, the National Biodefense Analysis and Countermeasures Center, the United States Army Medical Research Institute of Infectious Disease, Sandia National Laboratories, the California Department of Public Health and numerous others.
Dr. Satterfield remarked, “I am pleased to present the details of the rapid development of our COVID-19 test to the Bipartisan Commission on Biodefense. The Company’s proprietary platform serves as a template to develop other tests needed now, and in the future as new pathogens surface in our interconnected world. Our current test detects COVID-19 with a high level of specificity to distinguish it from similar viruses. However, in addition to recently being declared a pandemic by the World Health Organization, the virus that causes COVID-19 is also believed to be mutating. Co-Diagnostics’ patented CoPrimer technology is uniquely suited to quickly develop multiplex assays that can identify multiple mutations of the virus in a single test when the need arises. Rapid, efficient development of multiplexed tests is a core competency of Co-Diagnostics.” -
CDC is responding to an outbreak of respiratory disease caused by a novel (new) coronavirus that was first detected in China and which has now been detected in more than 100 locations internationally, including in the United States. The virus has been named “SARS-CoV-2” and the disease it causes has been named “coronavirus disease 2019” (abbreviated “COVID-19”).
-
-
PRECHECK HEALTH SERVICES - ON MARCH 9, 2020, ENTERED INTO DISTRIBUTION AGREEMENT WITH CO-DIAGNOSTICS INC - SEC FILING
-
PRECHECK HEALTH SERVICES - UNDER AGREEMENT, CO-DIAGNOSTICS GRANTED CO EXCLUSIVE DISTRIBUTION RIGHTS TO ITS QPCR INFECTIOUS DISEASE KITS FOR RUSSIA
ADVERTISEMENT
ADVERTISEMENT
-
PRECHECK HEALTH SERVICES - DISTRIBUTION AGREEMENT HAS TERM OF ONE YEAR, BUT CAN BE TERMINATED BY EITHER PARTY AT ANY ON 30 DAYS’ NOTICE
-
PRECHECK HEALTH - UNDER AGREEMENT CO-DIAGNOSTICS ALSO GRANTED CO EXCLUSIVE DISTRIBUTION RIGHTS TO LOGIX SMART COVID-19 PCR DIAGNOSTIC TEST FOR RUSSIA
-
PRECHECK HEALTH SERVICES - UNDER AGREEMENT, CO-DIAGNOSTICS ALSO GRANTED CO EXCLUSIVE DISTRIBUTION RIGHTS TO ITS CO-DX BOX(TM) INSTRUMENT FOR RUSSIA
-
-
We to go not
-
Don’t sell
-
Wtf let it ride
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Inovio Pharmaceuticals, Inc. – INO
GlobeNewswire
March 10, 2020, 4:36 pm
NEW YORK, March 10, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Inovio Pharmaceuticals, Inc. (“Inovio” or the “Company”) (NASDAQ: INO). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Inovio and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
-
This Company expects to pursue U.S. regulatory clearance and expects to consult with the U.S. Food and Drug Administration about qualifying the test under FDA's Emergency Use Authorization.
The Company expects to receive an initial product shipment in three to four weeks, pending the timing of required regulatory, customs, and importation activities. ITS NOT READY YET
-
This Company expects to receive an initial product shipment in three to four weeks, pending the timing of required regulatory, customs, and importation activities.
-
H.C. Wainwright Reiterates Buy on Co-Diagnostics (NASDAQ:CODX) with a $20 PT as Shipments to U.S and Overseas Markets Continue
Co-Diagnostics price target raised to $20 at H.C. Wainwright
March 10, 2020 15:11 ET | Source: BDA International
NEW YORK CITY, March 10, 2020 (GLOBE NEWSWIRE) -- H.C. Wainwright analyst Yi Chen released additional coverage on Co-Diagnostics (NASDAQ:CODX), a Utah-based molecular diagnostics company, raising the firm’s price target to $20 and keeping a Buy rating on the shares. Co-Diagnostics was the first U.S. company to receive CE Marking designation for a COVID-19 test, Chen tells investors in a research note. The analyst believes a recent FDA policy change to help expedite the availability of COVID-19 coronavirus diagnostics could be a significant boost to the company's potential sales of its COVID-19 test domestically.Co-Diagnostics is now shipping its proprietary COVID-19 test to countries across four continents, including America, Europe, Asia and Australia, said the analysts, adding “the domestic and international demand for COVID-19 tests has been surging in the past weeks.”
The company has been seeing an increase in product shipments of its Logix Smart COVID-19 screening test following the US Food and Drug Administration’s decision late last month to allow labs that meet a set of standards known as the Clinical Laboratory Improvement Amendments (CLIA) to use coronavirus detection tests that have been validated by the laboratories, even before the FDA has completed the review of the labs’ Emergency Use Authorization (EUA) submission.
Previously, labs seeking to use coronavirus tests had to wait for specific clearance from the FDA.
This recent activity coincides with the company completing a registered direct offering of 470K shares at $9 per share for gross proceeds of $4.2M, which leads the analyst to estimate that the company’s pro forma cash position post offering could approximate $24M, which should fund operations for the next three years.
According to the Wainwright analyst:
“In view of the continuing—and rapidly accelerating—COVID-19 infection spread worldwide and initialization of shipments to U.S. labs, we have increased the enterprise value-to-sales (EV/Sales) multiple to 12x from 10x and projected 2020 total sales to $1.66 from $0.40 per share, which leads to a value of $20 per share. Therefore, we reiterate our Buy rating while raising the 12-month target to $20 from $4 per share.”
The full research report can be accessed here.
Disclosure: Co-Diagnostics Inc is a client of BDA International.
About BDA International, Inc.:
BDA International is an independent global Investor Relations firm offering a wide range of IR-related analysis, research and advisory services. In particular, we provide and are compensated for service packages that include strategic action plans and investor/market perception studies to help entities improve communication with customers and investors, and to increase their visibility. BDA International has received no direct compensation related to this release but its principles hold shares of client companies in our personal portfolios, including CODX. BDA International accepts sole responsibility for the content and distribution of the foregoing release, which does not contain any previously unpublished or non-public information. Parties interested in learning more about the relationship between BDA and CODX may do so via the contact information at the bottom of this release
CODX
CODX
OPK
CODX
IBIO
CODX
CODX
CODX
CODX
CODX
CODX
CODX
CODX
CODX
INO
AYTU
AYTU
CODX
CODX
CODX